semaglutide cv outcomes and Cardiovascular in Obesity without Diabetes Abstract 4351008: Comparing Cardiovascular Outcomes

Study details Roughly 10% of tirzepatide users who lost more than 20% of their total body weight were found to have lost more than 5% of their lean body mass

Basu A, Charkoudian N, Schrage W, Rizza RA, Basu R, Joyner MJ

Researchers should add one compound at a time, assess tolerance, and avoid the temptation to implement complex protocols immediately

DSIP works faster, with sleep pressure reported within hours, but even its full effects on sleep architecture normalization develop over multiple doses

Among these patients, lean mass accounted for approximately 39% of total weight loss substantially higher than ideal

that 20% may not reflect 100% on injectable Wegovy and may be a mix of semaglutide as well as tirzepatide